戻る Agenda
CRISPR: Regulatory Challenges in the Gene Editing Revolution
Session Chair(s)
Nancy Bradish Myers, JD
CEO and Founder
Catalyst Healthcare Consulting, United States
This panel will explore the implications of CRISPR technology for product development and how it could bring significant changes in our treatment of disease. Panelists will discuss: the forces that will either drive the technology forward or potentially hold it up; how FDA is approaching CRISPR regulation; and global collaborative efforts to establish guiding principles for regulators.
Learning Objective : Discuss the potential for gene editing technology to revolutionize disease management; Recall perspectives on how the technology can be used.
Speaker(s)
FDA Perspective
Ritu Nalubola, PHD
FDA, Belgium
Director, FDA Europe Office
Panelist
Kurt von Emster, CPA
Abingworth, United States
Managing Partner
Panelist
Eva Essig
Intellia Therapeutics, Inc., United States
Vice President, Regulatory Affairs